Applying cytogenetic and molecular information in the clinic: Implications for the treatment of chronic myeloid leukemia

Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge E. Cortés

Research output: Contribution to journalArticle

Abstract

The tyrosine kinase inhibitor (TKI) imatinib mesylate has changed dramatically the outcome of patients with chronic myeloid leukemia (CML). Most patients chieve a complete cytogenetic response (CCyR), and many also achieve profound molecular responses. These excellent clinical responses translate into very favorable long-term outcomes. The prognostic impact of achieving cytogenetic and molecular responses at specific time points on response duration and survival has made it even more important to appropriately monitor TKI response in patients with CML. To this end, sophisticated molecular techniques are increasingly available to clinical laboratories. The clinical implications of TKI response monitoring in CML are herein reviewed.

Original languageEnglish (US)
Pages (from-to)S14-S19
JournalClinical Lymphoma, Myeloma and Leukemia
Volume10
Issue numberSUPPL. 1
DOIs
StatePublished - Jun 2010
Externally publishedYes

Keywords

  • BCR-ABL1
  • Dasatinib
  • Fluorescence in situ hybridization
  • Imatinib
  • Nilotinib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Applying cytogenetic and molecular information in the clinic: Implications for the treatment of chronic myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this